You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
現代製藥(600420.SH):鹽酸右美託咪定注射液獲得藥品註冊批件
格隆匯 07-24 15:58

格隆匯7月24日丨現代製藥(600420.SH)宣佈,近日,公司全資子公司國工有限收到國家藥品監督管理局核准簽發的“鹽酸右美託咪定注射液”藥品註冊批件。鹽酸右美託咪定注射液主要用於行全身麻醉的手術患者氣管插管和機械通氣時的鎮靜。截至目前公司在該項目中累計投入研發費用約人民幣641.36萬元(未經審計)。

該藥品由Abbott Laboratories(美國)和Orion Pharm(芬蘭)共同開發研製,於1999年12月首次獲得美國FDA批准上市。CDE網站顯示,鹽酸右美託咪定注射液國內已有江蘇恆瑞醫藥股份有限公司、辰欣藥業股份有限公司、江蘇恩華藥業股份有限公司等10家企業獲批上市;目前該藥品視同通過一致性評價的公司為國工有限及揚子江藥業集團有限公司。

根據米內網數據庫顯示,鹽酸右美託咪定注射液2019年在全國城市樣本公立醫院的銷售額為人民幣28.72億元。

公司表示,此次全資子公司國工有限的鹽酸右美託咪定注射液獲得藥品註冊批件並視同通過一致性評價,將進一步豐富公司麻精鎮痛板塊產品線,實現鹽酸右美託咪定藥和製劑產品的產業鏈一體化,有助於提升公司產品的市場競爭力,為公司未來發展帶來積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account